ArticleBritish journal of haematology2022
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
Article in British journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.Nature cancer · 2025Trial
- Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients.British journal of haematology · 2026Article
- Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma.International journal of hematology · 2026Article
- A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers.Clinical pharmacology in drug development · 2026Article
- Could treatment modification based on early response assessment improve results in DLBCL?Hematology. American Society of Hematology. Education Program · 2025Review
- Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study.The oncologist · 2025Observational
- Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up.Blood advances · 2025Article
- Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis.Blood neoplasia · 2025Article
- Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies.British journal of haematology · 2025Article
- Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.Therapeutic advances in medical oncology · 2025Article
- Article
- Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.Oncology and therapy · 2024Article
- Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands.Blood cancer journal · 2024Article
- CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?Seminars in hematology · 2023Review
- Autologous Transplantation May Still Effectively Treat Relapsed Diffuse Large B-Cell Lymphoma in Selected Patients.Cancers · 2023Article
- Clinical and Therapeutic Profile of Non-Hodgkin's Lymphoma: A Retrospective Study From a Najran Oncology Center.Cureus · 2023Article
- Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.Blood advances · 2022Article
- Article
- Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.British journal of haematology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several recently published trials investigate novel therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). To estimate the benefit of these therapies in the real-world setting, comprehensive data on patients treated in clinical routine are needed. We report outcomes for 736 R/R DLBCL patients identified among all curatively treated DLBCL patients in Sweden in the period 2007-2014. Survival and associations with disease characteristics, second-line treatment and fulfilment of chimaeric antigen receptor (CAR) T-cell trial criteria were assessed. Median overall survival (OS) was 6.6 months (≤70 years 9.6 months, >70 years 4.9 months). Early relapse (≤12 months) was strongly associated with selection of less intensive treatment and poor survival. Among patients of at most 70 years of age, 63% started intensive second-line treatment and 34% received autologous stem cell transplantation (ASCT). Two-year OS among transplanted patients was 56% (early relapse ≤12 months 40%, late relapse >12 months 66%). A minority of patients 76 years (n = 178/506, 35%) fitted CAR T trial criteria. Median progression-free survival (PFS) for patients with early relapse fitting trial criteria was 4.8 months. In conclusion, most R/R DLBCL manifest early and are often ineligible for or cannot complete intensive regimens resulting in dismal survival. Real-world patients eligible for CAR T trials also did poorly, providing a benchmark for efficacy of novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.